Company intelligence / Profile preview

JHM Biopharm

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

JHM Biopharm is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) platform to create therapies for metabolic diseases, autoimmune disorders, and oncology. Its lead program, JHM-2094, is a highly selective URAT1 inhibitor being developed for the treatment of gout and hyperuricemia. JHM Biopharm's pipeline also includes promising candidates targeting TYK2 and GLP-1R, aiming to provide next-generation oral treatments for chronic conditions.

Therapeutic areas: EndocrinologyRheumatologyDermatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on JHM Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JHM Biopharm.

Explore the full profile